Bladder Cancer

"When we think about a typical procedure for performing a radical cystectomy for cancer with an ileal conduit, that would typically involve lymph node dissection, and therefore CPT 51595 would be best chosen to report that combined procedure," write Jonathan Rubenstein, MD, and Mark Painter.

Data from the EV-302 trial showed a doubling of progression-free survival and overall survival with the ADC/checkpoint combination versus standard chemotherapy.

Neal Shore, MD, FACS, offers clinical insights on optimizing patient selection and treatment sequencing in BCG-unresponsive NMIBC.

This monthly series will begin in January 2024, and attendees can earn one category 1 CME credit per session.

Sam S. Chang MD, MBA leads a discussion of various treatment approaches for a hypothetical case of a 74-year-old female patient with T1 bladder cancer and associated CIS, exploring the necessity of repeat resections. The conversation emphasizes the importance of personalized treatment plans, considering BCG therapy, clinical trials involving immunotherapy, and the possibility of cystectomy, while also addressing the complexities and risks associated with high-grade bladder cancer in elderly patients.

This episode focuses on the complex management of recurrent low-grade bladder tumors and highlights the limitations and challenges of current treatments, including intravesical chemotherapy and BCG, and underscores the need for better therapies and clinical trials in this area.

“The primary outcome will be feasibility of in-home treatments,” says Timothy D. Lyon, MD, FACS.

“We were pleased and excited to see that 72% of patients reported openness to receiving in-home intravesical therapy,” says Timothy D. Lyon, MD, FACS.

The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.

A urologist discusses treatments in the pipeline that can further improve the therapeutic landscape in BCG-unresponsive NMIBC.

The panel discusses the Large Urology Group Practice Association and provides insights on collaborative care approaches in bladder cancer.

Comprehensive insights on the unmet needs addressed by TAR-200 in BCG-unresponsive non-muscle-invasive bladder cancer.

The various treatment approaches for NMIBC in the context of a BCG shortage, with a focus on initial cases, are shared. Urologists discuss their strategies for treating a hypothetical patient with a 3 cm bladder tumor, weighing options like perioperative chemotherapy, the importance of thorough resection, and adapting treatment protocols based on tumor characteristics and the ongoing BCG shortage.

The impact of the BCG shortage on the treatment of bladder cancer, exploring various strategies adopted by urologists to optimize patient care. The conversation highlights the importance of risk stratification in deciding treatment protocols, considering factors like tumor size, location, multifocality, and histology, as well as patient age and overall health.

As the year comes to a close, we revisit some of this year’s top content on bladder cancer.

Neal Shore, MD, FACS, reviews agents and treatment options being researched in the BCG-unresponsive NMIBC treatment space.

Following a review of the limitations of current treatment options, Neal Shore, MD, MFACS, discusses the SunRISe-1 trial investigating TAR-200 plus cetrelimab in patients with high-risk NMIBC.

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

"The Bladder CARE Assay's quantitative nature sets it apart from other tests," said Siamak Daneshmand, MD.

Experts discuss grading, staging, and risk stratification of Non-Muscle Invasive Bladder Cancer (NMIBC). Panelists highlight differentiation between the risks of recurrence and progression, emphasizing the importance of categorizing patients into low, intermediate, and high-risk groups based on various factors, including tumor size, grade, and history of recurrence. The importance of continuous prospective observation of patients with NMIBC is emphasized.

Experts in urology discuss the importance of evaluation to accurately identify the stage and grade of NMIBC, which plays a crucial role in determining the risk category focusing on the distinction between low and high-grade tumors and the significance for each patient with NMIBC​​.

“When it comes to this, I think having a great team around you is really so important,” says Bree Duncan, RN, BSN.

The approval is supported by findings from the phase 3 EV-302 trial, which showed that the combination led to significant improvements in overall survival and progression-free survival compared with chemotherapy.

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

A panel of experts on bladder cancer provide an overview of the stratification, natural history, and treatment of bladder cancer.

An expert urologist reviews the clinical hallmarks of high-risk BCG-unresponsive NMIBC and discusses the unmet needs and treatment goals.

Neal Shore, MD, FACS, provides an overview of BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), with a focus on patient presentation and risk stratification.